• LAST PRICE
    0.6620
  • TODAY'S CHANGE (%)
    Trending Up0.0777 (13.2980%)
  • Bid / Lots
    0.6620/ 10
  • Ask / Lots
    0.6999/ 4
  • Open / Previous Close
    0.7900 / 0.5843
  • Day Range
    Low 0.6500
    High 0.7900
  • 52 Week Range
    Low 0.3400
    High 4.4000
  • Volume
    320,827
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.5843
TimeVolumePRTG
09:32 ET1140010.73349
09:33 ET259790.65011
09:35 ET4000.68
09:37 ET26420.69
09:39 ET87750.7189
09:42 ET37940.663121
09:46 ET9620.7
09:50 ET2710.6521
09:51 ET6000.6561
09:53 ET31400.6525
09:55 ET1990.6858
09:57 ET10000.68
10:00 ET5000.670999
10:02 ET6000.68
10:06 ET4690.663
10:08 ET16000.662
10:09 ET9500.6691
10:15 ET103200.6819
10:18 ET4000.682
10:20 ET6000.68
10:22 ET15630.699
10:24 ET29560.699
10:26 ET20000.7
10:27 ET11320.7
10:29 ET1000.6691
10:36 ET10970.6621
10:45 ET3000.6531
10:47 ET1000.653
10:49 ET5890.653
11:02 ET60100.692475
11:03 ET11000.6925
11:05 ET26000.6808
11:18 ET8000.662
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRTG
Portage Biotech Inc
11.6M
-0.1x
---
United StatesMBIO
Mustang Bio Inc
11.6M
-0.2x
---
United StatesTXTM
Protext Mobility Inc
11.4M
0.0x
---
United StatesDOMH
Dominari Holdings Inc
11.2M
-0.4x
---
United StatesBCEL
Atreca Inc
12.0M
-0.1x
---
United StatesCEOS
CeCors Inc
11.0M
0.0x
---
As of 2024-02-26

Company Information

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

Contact Information

Headquarters
Clarence Thomas Building, Road Town P.O. Box 4649TORTOLA, ON, Virgin Islands (British) VG1110
Phone
416-929-1806
Fax
416-929-6612

Executives

Chairman of the Board, Chief Executive Officer
Ian Walters
Chief Financial Officer, Secretary
Allan Shaw
Chief Scientific Officer
Robert Kramer
Vice President - Project Management and Operations
Steven Innaimo
Vice President - Development
Justin Fairchild

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.6M
Revenue (TTM)
$0.00
Shares Outstanding
19.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-6.52
Book Value
$4.32
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.